Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Oncolytic Virus, CAR T Combination Preclinical Study Shows Activity in Solid Tumors
February 24th 2021Loading chimeric antigen receptor (CAR) T-cells with the oncolytic virus pelareorep improved their efficacy in solid tumor mouse models in a preclinical study presented at the CAR-TCR Summit Europe 2021.
Read More
FDA Approves Cemiplimab for First-Line Advanced NSCLC With PD-L1 Expression
February 22nd 2021The PD-1 inhibitor cemiplimab-rwlc, sold as Libtayo, was FDA approved as a monotherapy for patients with first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Read More
Study Suggests Certain Types of Patent Foramen Ovale May Be Associated With Migraine
February 20th 2021Patent foramen ovale (PFO) may be associated with migraine, especially migraine with aura (MA), when the PFO is permanent right-left shunt (RLS), large RLS, and large-size PFO, a recent study found.
Read More
Central Retinal Artery Occlusion Rates in Korea Decreased Over Time, Study Finds
February 19th 2021Rates of central retinal artery occlusion (CRAO), which is associated with and shares common risk factors with cardiovascular diseases, have decreased over time in Korea, a recent cohort study of 50 million residents found.
Read More
FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC
February 16th 2021The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.
Read More
Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show
February 16th 2021A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.
Read More
Possible Treatment Identified for Aggressive NSCLC Subset
February 16th 2021Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.
Read More
Sustained MRD Negativity Predictive of Long-term Outcomes in RRMM
February 16th 2021Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.
Read More
Carfilzomib Improves Renal Response Compared With Bortezomib in RRMM
February 12th 2021Carfilzomib-dexamethasone improved renal overall and complete response in patients with relapsed or refractory multiple myeloma (RRMM) compared with a regimen of bortezomib-dexamethasone in a real-world study.
Read More
Study Finds Shorter Radiation Regimen Safe, Effective for Advanced Prostate Cancer
January 30th 2021Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.
Read More